In light of the molecular heterogeneity amongst luminal tumours,22 and the reduction in the cut-off value for defining ER+ cancers from 10% to 1% of positively stained cells,141 the fact that women with HR+ tumours present with ER– DTCs is perhaps not much of a surprise, per se. The gene discussed is ESR1; the disease is cancer.